Options and opportunities for clinical management and treatment of psoriasis

Critical Reviews in Therapeutic Drug Carrier Systems

Volumn 30, Issue 1, 2013, Pages 51-90

  Agrawal, Udita ^a   Gupta, Madhu ^a   Dube, Devyani ^a   Vyas, Suresh P ^a  

^a DR H S GOUR UNIVERSITY   (India)

Author keywords

Novel carriers; Pathogenesis; Psoriasis; Treatment approach

Indexed keywords

ABATACEPT; ADALIMUMAB; ALEFACEPT; AMINOLEVULINIC ACID; BASILIXIMAB; CALCIPOTRIOL; COAL TAR; CORTICOSTEROID; CYCLOSPORIN; DACLIZUMAB; DENILEUKIN DIFTITOX; DITHRANOL; EFALIZUMAB; ETANERCEPT; ETRETIN; FUMARIC ACID ETHYL ESTER; GALIXIMAB; INFLIXIMAB; LIPOSOME; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NIOSOME; ONTAX; ORENICA; PSORALEN; RAMICADE; RETINOID; SALICYLIC ACID; TAZAROTENE; TIOGUANINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; USTEKINUMAB; VITAMIN D; ZENEPAX;

ANGIOGENESIS; ANOREXIA; ANTIGEN PRESENTING CELL; ARTICLE; BONE MARROW SUPPRESSION; BURN; CELL DIFFERENTIATION; CONSTIPATION; CUSHING SYNDROME; DISEASE SEVERITY; DNA SYNTHESIS; DRUG DELIVERY SYSTEM; DRY SKIN; DYSURIA; EDEMA; FOLLICULITIS; GASTROINTESTINAL DISEASE; HEMATURIA; HUMAN; HYPERCALCEMIA; HYPERTENSION; IMMUNE RESPONSE; INFLAMMATION; IRRITANT DERMATITIS; KERATINOCYTE; LEUKOCYTE; MACROCYTIC ANEMIA; MAJOR HISTOCOMPATIBILITY COMPLEX; MICROEMULSION; NAUSEA; NONHUMAN; PAPILLOMA VIRUS; PERIORAL DERMATITIS; PHOTOTHERAPY; PREVALENCE; PRURITUS; PSORIASIS; SKIN ABRASION; SKIN ATROPHY; SKIN IRRITATION; SKIN TOXICITY; STOMATITIS; STRIA; T LYMPHOCYTE; TELANGIECTASIA; TRANSGENIC ORGANISM; ULTRAVIOLET RADIATION; UPREGULATION; VOMITING; XENOGRAFT;

ANIMALS; HUMANS; PSORIASIS;

EID: 84875198313     PISSN: 07434863     EISSN: 2162660X     Source Type: Journal    
DOI: 10.1615/CritRevTherDrugCarrierSyst.2013005589     Document Type: Article

References (146)

1. Weinberg JM. Medical backgrounder: psoriasis. Drugs Today. 2002;38:847-65.
2. Lebwohl M. Psoriasis. Lancet. 2003; 361:1197-204.
3. Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol. 2002:46:1-23.
4. Nickoloff BJ, Nestle FO. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest. 2004;113,1664-75.
5. Singri P, West DP, Gordon KB. Biologic therapy for psoriasis: the new therapeutic frontier. Arch Derm. 2002;138:657-63.
6. Zhou S, Matsuyoshi N, Takeuchi T, Ohtsuki Y, Miyachi Y. Reciprocal altered expression of T-cadherin and P-cadherin in psoriasis vulgaris. Br J Dermatol. 2003;149:268-73.
7. Barker JN. Genetic aspects of psoriasis. Clin Exp Dermatol. 2001;26:321-5.
8. Helms C, Cao L, Krueger JG, Wijsman EM, Chamian F, Gordon D, Heffernan M, Wright Daw JA, Robarge J, Ott J. A putative RUNX1 binding site variant between SLC9A3R1 and NAT9 is associated with susceptibility to psoriasis. Nat Genet. 2003;5:349-56.
9. Travers JB, Norris DA, Leung DYM. The keratinocyte as a target for staphylococcal bacterial toxins. J Invest Dermatol. 2001;6:225-30.
10. Baroni A, Paoletti I, Ruocco E, Agozzino M, Tufano MA, Donnarumma G. Possible role of Malassezia furfur in psoriasis: modulation of TGF-beta-1, integrin, and HSP70 expression in human keratinocytes and in the skin of psoriasis-affected patients. J Cutan Pathol. 2004; 31:35-42.
11. Doi H, Shibata MA, Kiyokane K, Otsuki Y. Down regulation of TGF beta isoforms and their receptors contributes to keratinocyte hyperproliferation in soriasis vulgaris. J Dermatol Sci. 2003;33:7-16.
12. Edmondson SR, Thumiger SP, Werther GA, Wraight CJ. Epidermal homeostasis: The role of the growth hormone and insulin-like growth factor systems. Endocr Rev. 2003;24:737-64.
13. Oyama N, Takahashi H, Tojo M, Iwatsuki K, Iizuka H, Nakamura K, Homma Y, Kaneko F. Different properties of three isoforms (alpha, beta, and gamma) of transcription factor AP-2 in the expression of human keratinocyte genes. Arch Dermatol Res. 2002;294:273-80.
14. Matsuzaka Y, Okamoto K, Tsuji H, Mabuchi T, Ozawa A, Tamiya G, Inoko H. Identification of the hRDH-E2 gene, a novel member of the SDR family, and its increased expression in psoriatic lesion. Biochem Biophys Res Commun. 2002;297:1171-80.
15. Leonardi CL. Efalizumab: an overview. J AmAcad Dermatol. 2003;49:S98-S104.
16. Ghoreschi K, Thomas P, Breit S, Dugas M, Mailhammer R, van Eden W, van der Zee R, Biedermann T, Prinz J, Mack M. Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. Nat Med. 2003;9:40-6.
17. Krueger G, Ellis CN. Psoriasis-recent advances in understanding its pathogenesis and treatment. J Am Acad Dermatol. 2005;53:s94-s100.
18. Villadsen LS, Schuurman J, Beurskens F, Dam TN, Dagnaes-Hansen F, Skov L. Resolution of psoriasis upon blockade of IL-15 biological activity in a xenograft mouse model. J Clin Invest. 2003;112:1571-80.
19. Blumberg H, Conkin D, Xu W, Grossman A, Brender T, Carollo S, Eagan M, Foster D, Haldeman BA, Hammond A. Interleukin 20: discovery, receptor identification, and role in epidermal function. Cell. 2001;104:9-19.
20. Creamer D, Sullivan D, Bicknell R, Barker J. Angiogenesis in psoriasis. Angiogenesis. 2002; 5:231-6.
21. Miriam C, Fiorella A, Thomas R, Schauber Jü rgen. Vascular endothelial growth factor (VEGF) in the pathogenesis of psoriasis-a possible target for novel therapies? J Dermat Sci. 2010; 58: 171-6.
22. Kuroda K, Sapadin A, Shoji T. Altered expression of angiopoietins and Tie2 endothelium receptor in psoriasis. J Invest Dermatol.2001;116:713-20.
23. Sauder DN, DeKoven J, Champagne P, Croteau D, DuPont E. Neovastat (AE941), an inhibitor of angiogenesis: randomized phase I/II clinical trial results in patients with plaque psoriasis. J Am Acad Dermatol. 2002;47:535-41.
24. Camisa C. Psoriasis: a clinical update on diagnosis and new therapies. Cleve Clin J Med. 2000; 27. 67:105-13, 117.
25. Zanolli M. Phototherapy treatment of psoriasis today. J Am Acad Dermatol. 2003;49:S78-86.
26. Peters BP, Weissman FG, Maka G. Pathophysiology and treatment of psoriasis. Am J Health Syst Pharm. 2000;57:645-62.
27. Weinstein GD, Gottlieb AB: Therapy of moderate-to-severe psoriasis. Up-to-date reviews of available traditional and biologic therapies. New York: Marcel Dekker, Inc.; 2003.
28. Menter MA, Krueger GC, Feldman SR, Weinstein GD. Psoriasis treatment 2003 at the new millennium: position paper on behalf of authors. J Am Acad Dermatol. 2003;49(Suppl): S39-43.
29. Su Y-H, Fang J-Y. Drug delivery and formulations for topical treatment of psoriasis. Exp Opin Drug Deliv 2008;5:235-49.
30. Mason AR, Mason J, Cork M, Dooley G, Edwards G. Topical treatments for chronic plaque psoriasis. Cochrane Database Syst Rev 2009; CD005028. DOI: 10.1002/14651858.
31. Hegyi Z, Zwicker S, Bureik D, Peric M, Koglin S, Batycka-Baran A, Prinz JC, Ruzicka T, Schauber J, Wolf R. Vitamin D analog calcipotriol suppresses the Th17 cytokine-induced proinflammatory S100 "alarmins" psoriasin (S100A7) and koebnerisin (S100A15) in psoriasis. J Invest Dermatol. 2012;132(5):1416-24.
32. Mendonc CO, Burden AD. Pharmacology & Therapeutics Current concepts in psoriasis and its treatment. 2003;99:133-47.
33. Guenther LC, Ortonne JP. Pathophysiology of psoriasis: science behind therapy. J Cutan Med Surg. 2002;6:2-7.
34. Horn EJ, Domm S, Katz HI, Lebwohl M, Mrowietz U, Kragballe K. Topical corticosteroids in psoriasis: strategies for improving safety. J Eur Acad Dermatol Venereol. 2010;24:119-24.
35. Topical corticosteroids in psoriasis: strategies for improving safety. J Eur Acad Dermatol Venereol. 2010;24:119-24
36. Katz HI, Prawer SE, Medansky RS, Krueger GG, Mooney JJ, Jones ML, Samson CR. Intermittent corticosteroid maintenance treatment of psoriasis: a double-blind multicenter trial of augmented betamethasone dipropionate ointment in a pulse dose treatment regimen. Dermatologica. 1991;183(4):269-74.
37. Miller JJ, Roling D, Margolis D, Guzzo C. Failure to demonstrate therapeutic tachyphylaxis to topically applied steroids in patients with psoriasis. J Am Acad Dermatol.1999;41:546-9.
38. Tauscher AE, Fleischer AB Jr, Phelps KC, Feldman SR. Psoriasis and pregnancy. J Cutan Med Surg. 2002;6:561-70.
39. Feldman SR, Yentzer BA. Topical clobetasol propionate in the treatment of psoriasis: a review of newer formulations. Am J Clin Dermatol. 2009;10:397-406.
40. Ellis CN, Krueger GG. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med. 2001;245:248-55.
41. Ronpirin C, Tencomnao T. Effects of the antipsoriatic drug dithranol on E2A and caspase-9 gene expression in vitro. Gen Mol Res. 2012;11(1): 412-20.
42. Wollina U, Koch A, Scheibe A, Seme B., Streit I, Schmidt WD. Targeted 307 nm UVB-excimer light vs. topical dithranol in psoriasis. J Eur Acad Dermatol Venereol. 2012;26(1):122-3.
43. Koek MB, Buskens E, van Weelden H, Steegmans PH, Bruijnzeel-Koomen CA, Sigurdsson V. Home versus outpatient ultraviolet B phototherapy for mild to severe psoriasis: pragmatic multicentre randomised controlled non-inferiority trial (PLUTO study). BMJ;2009: 338:b1542. doi: 10.1136/bmj.b1542.
44. Goodfield M, Kownacki S, Berth-Jones J. Double-blind, randomised, multicentre, parallel group study comparing a 1% coal tar preparation (Exorex) with a 5% coal tar preparation (Alphosyl) in chronic plaque psoriasis. J Dermatol Treat. 2004; 15:14-22.
45. van de Kerkhof PC. Update on retinoid therapy of psoriasis in an update on the use of retinoids in dermatology. Dermatol Ther. 2006;19:252-63.
46. Veraldi S, Caputo R, Pacifico A, Peris K, Soda R, Chimenti S. Short contact therapy with tazarotene in psoriasis vulgaris. Dermatol. 2006; 212:235-7.
47. Weinstein GD, Koo JY, Krueger GG. Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks. J Am Acad Dermatol. 2003;48:760-7.
48. Tzung TY, Wu JC, Hsu NJ. Comparison of tazarotene 0.1% gel plus petrolatum once daily versus calcipotriol 0.005% ointment twice daily in the treatment of plaque psoriasis. Acta Derm Venereol. 2005;85:236-9.
49. Stern RS. Psoralen and ultraviolet a light therapy for psoriasis. N Engl J Med. 2007; 357:682-90.
50. Gruss C, Behren S, Reuther T, Husebo L, Neumann N, Altmeyer P, Lehman P, Kerscher M. Kinetics of photosensitivity in bath-PUVA photochemotherapy. J Am Acad Dermatol.1998;89:443-6.
51. Umezawa Y, Mabuch T, Ozawa A. Generalized pustular psoriasis in a child: observation of long-term combination therapy with etretinate and calcipotriol for 16 years. Pediatr Dermatol. 2012;29(2):206-8.
52. Gollnick HPM. Oral retinoids-efficacy and toxicity in psoriasis. Br J Dermatol.1996;135:6-17.
53. Verfaille CJ, Vanhoutte FP, Blanchet-Bardon C, van Steensel MA, Steijlen PM. Oral liarozole vs. acitretin in the treatment of ichthyosis: a phase II/III multicentre, double-blind, randomized, active-controlled study. Br J Dermatol. 2007;156(5):965-73.
54. Khaled A, Ben Hamida M, Zeglaoui F, Kharfi M, Ezzine N, Fazaa B. Treatment of psoriasis by methotrexate in the era of biotherapies: a study in 21 tunisian patients. Therapie. 2012;67(1):49-52.
55. Kaur I, Dogra S, De D, Kanwar AJ. Systemic methotrexate treatment in childhood psoriasis: further experience in 24 children from India. Pediatr Dermatol. 2008;25(2):184-8.
56. Mitra A, Wu Y. Topical delivery for the treatment of psoriasis. Expert Opin Drug Deliv. 2010; 7:977-92.
57. Rosmarin DM, Lebwohl M, Elewski BE, Gottlieb AB. Cyclosporine and psoriasis: 2008 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol. 2010; 62:838-53.
58. Kamarasheva J, Lora P, Forsterb A, Heinzerlinga L, Burga G, Nestlea FO. Generalised pustular psoriasis induced by cyclosporin A withdrawal responding to the tumour necrosis factor alpha inhibitor etanercept. Dermatol. 2002;205:213-216.
59. Ruihua Wang, Longnian Li, Bing Wang, Tangde Zhang, Ledong Sun. FK506-loaded solid lipid nanoparticles: Preparation, characterization and in vitro transdermal drug delivery. African J Pharma Pharmacol. 2012; 6(12), 904-13.
60. Ormerod AD, Shah SA, Copeland P, Omar G, Winfield A. Treatment of psoriasis with topical sirolimus: preclinical development and a randomized, double-blind trial. Br J Der matol. 2005;152(4):758-64.
61. Menter Alan, Griffiths CEM. Current and future management of psoriasis. Lancet. 2007; 370: 272-84.
62. Pietrzak AT, Zalewska A, Chodorowska G, Krasowska D, Michalak-Stoma A, Nockowski P, Osemlak P, Paszkowski T, Roliński JM. Cytokines and anticytokines in psoriasis. Clinica Chimica Acta. 2008;394:7-21.
63. Gottlieb AB. Psoriasis, immunopathology and immunomodulation. Dermatol Clin.2001;19: 649-57.
64. Gottlieb AB, Krueger JG, Wittkowski K, Dendrick RWPA, Gavaroy M. Psoriasis as a model for T-cell-mediated disease. Immunobiological and clinical effects of treatment with multiple doses of Efalizumab, an anti-CD11a antibody. Arch Dermatol. 2002;138:591-600.
65. Tyring S, Gottlieb A, Papp K. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet. 2006;367:29-35.
66. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000; 356: 385-90.
67. Benjamin FC, Henry KW. Immunobiologics in the treatment of psoriasis. Clin Immunol. 2007; 123:129-38.
68. Gupta M, Agrawal U, Vyas SP. Nanocarrier-based topical drug delivery for the treatment of skin diseases. Exp Opin Drug Deliv. 2012; (doi:10.1517/17425247.2012.686490).
69. Katare OP, Raza K, Singh B, Dogra S. Novel drug delivery systems in topical treatment of psoriasis: Rigors and vigors. Ind J Dermatol Venereol Leprol. 2010;76:612-21.
70. de Leeuw J, de Vijlder HC, Bjerring P, Neumann HA. Liposomes in dermatology today. J Eur Acad Dermatol Venereol.2009;23:505-16.
71. Ali J, Akhtar N, Sultana Y, Baboota S, Ahuja A. Antipsoriatic microemulsion gel formulations for topical drug delivery of babchi oil (Psoralea corylifolia). Methods Find Exp Clin Pharmacol. 2008;30(4):277-85.
72. Pardeike J, Hommoss A, Muller RH. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int J Pharm. 2009;366:170-84.
73. Singh B, Kapil R, Bandopadhyay S, Katare OP. Dendrimers as nanobiopolymers: Drug delivery applications. Pharma Buzz. 2009;34-43.
74. Uchegbu IF, Vyas SP. Non-ionic surfactant based vesicles (niosomes) in drug delivery. Int J Pharm. 1998;172:33-70.
75. Morganti P, Ruocco E, Wolf R, Ruocco V. Percutaneous absorption and delivery systems. Clin Dermatol. 2001;19:489-501.
76. Tamilvanan S, Venkateshan N, Ludwig A. The potential of lipid-and polymer-based drug delivery carriers for eradicating biofilm consortia on device-related nosocomial infections. J Cont Rel. 2008;128:2-22.
77. Agarwal R, Katare OP, Vyas SP. Preparation and in vitro evaluation of liposomal/niosomal delivery systems for antipsoriatic drug dithranol. Int J Pharm. 2001; 228:43-52.
78. Agarwal R, Saraswat A, Kaur I, Katare OP, Kumar B. A novel liposomal formulation of dithranol for psoriasis: preliminary results. J Dermatol 2002;29:529-32.
79. Bhatia A, Kumar R, Katare OP. Tamoxifen in topical liposomes: development, characterization and in-vitro evaluation. J Pharm Pharm Sci 2004;7:252-9.
80. Saraswat A, Agarwal R, Katare OP, Kaur I, Kumar B. A randomized, double-blind, vehicle-controlled study of a novel liposomal dithranol formulation in psoriasis. J Dermatol Treat. 2007;18:40-5.
81. Saraswat A, Agarwal R, Kaur I, Katare OP, Kumar B. Fabric-staining properties and washability of a novel liposomal dithranol formulation. J Dermatol Treat. 2002;13:119-22.
82. Erdogan M, Wright JR Jr, McAlister VC. Liposomal tacrolimus lotion as a novel topical agent for treatment of immune-mediated skin disorders: experimental studies in a murine model. Br J Dermatol. 2002;146:964-7.
83. Gidwani SK, Singnurkar PS. Composition for delivery of dithranol. India: European Patent Office: 2003: p. 1-14
84. Ali MF, Salah M, Rafea M, Saleh N, Liposomal methotrexate hydrogel for treatment of localized psoriasis: preparation, characterization and laser targeting. Med Sci Monit. 2008;14:I66-74.
85. Katare OP, Kumar R, Bhoop BS, Dogra S, Kaur I. A multicompartmental liposomal system for topical drug delivery. Kolkata (India): The Patent Office Journal. 2009;6210.
86. Knudsen NØ, Rønholt S, Salte RD, Jorgensen L, Thormann T, Basse LH, Hansen Jens, Frokjaer Sven, Foged Camilla. Calcipotriol delivery into the skin with PEGylated liposomes. Eur J Pharma Biopharm. 2012; PMID:22538098.
87. Katare OP, Sinha VR, Bhatia A, Kumar R, Gupta S. Synergistic liposomal tamoxifen composition for topical application and method of preparing thereof. United Nations: WIPO; 2006.
88. Bhatia A, Singh B, Bhushan S, Katare OP. Tamoxifen-encapsulated vesicular systems: cytotoxicity evaluation in human epidermal keratinocyte cell line. Drug Del Ind Pharm. 2010;36:350-4.
89. Prufer K, Jirikowski GF. Liposomal incorporation changes the effect of 1.25-dihydroxyvitamin D3 on the phospholipase C signal transduction pathway and the eicosanoid cascade on keratinocytes in vitro. Biochem Pharmacol. 1996;51:247-52.
90. Lakshmi PK, Devi GS, Bhaskaran S, Sacchidanand S. Niosomal methotrexate gel in the treatment of localized psoriasis: phase I and phase II studies. Ind J Dermatol Venereol Leprol. 2007;73:157-61.
91. Sutthanut K, Lu X, Jay M, Sripanidkulchai B. Solid lipid nanoparticles for topical administration of Kaempferia parviflora extracts. J Biomed Nanotechnol. 2009; 5(2):224-32.
92. Gupta M, Tiwari S, Vyas SP. Influence of various lipid core on characteristics of SLNs designed for topical delivery of fluconazole against cutaneous candidiasis. Pharm Dev Technol. 2011; doi:10.3109/10837450.2011.598161.
93. Misra AK, Padhi BK, Chougule M. Methotrexate-loaded solid lipid nanoparticles for topical treatment of psoriasis: formulation & clinical implications. Drug Deliv Tech. 2004;4:8.
94. Fang Jia-You, Fang Chia-Lang, Liu Chi-Hsien, Su Yu-Han. Lipid nanoparticles as vehicles for topical psoralen delivery: Solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC). Eur J Pharm Biopharm. 2008;70:633-40.
95. Shah AK, Date AA, Joshi MD, Patravale VB. Solid lipid nanoparticles (SLN) of tretinoin: potential in topical delivery. Int J Pharm. 2007;345:163-71.
96. Müller RH, Petersen RD, Hommoss A, Pardeike J. Nanostructured lipid carriers (NLC) in cosmetic dermal products. Adv Drug Deliv Rev. 2007;59:522-30.
97. Lin Yin-Ku, Huang Zih-Rou, Zhuo Rou-Zi, Fang Jia-You. Combination of calcipotriol and methotrexate in nanostructured lipid carriers for topical delivery. Int J Nanomed. 2010;5:117-28.
98. Peira E, Carlotti ME, Trotta C, Cavalli R, Trotta M. Positively charged microemulsions for topical application. Int J Pharm. 2008;346:119-23.
99. Baroli B, Lopez-Quintela MA, Delgado-Charro MB, Fadda AM, Blanco-Mendez J. Microemulsions for topical delivery of 8-methoxsalen. J Cont Rel. 2000;69:209-18.
100. Wu SX, Guo NR. Clinical observation on effect of triptolide tablet in treating patients with psoriasis vulgaris. Chin J Integr Med. 2005;11:147-8.
101. Mei Z, Chen H, Weng T, Yang Y, Yang X. Solid lipid nanoparticle and microemulsion for topical delivery of triptolide. Eur J Pharm Biopharm. 2003;56:189-96.
102. Chen H, Chang X, Weng T, Zhao X, Gao Z, Yang Y. A study of microemulsion systems for transdermal delivery of triptolide. J Cont Rel. 2004;98:427-36.
103. Baboota S, Alam M, Sharma S, Sahni JK, Kumar A, Ali J. Nanocarrier-based hydrogel of betamethasone dipropionate and salicylic acid for treatment of psoriasis. Int J Pharm. 2011;1:139-47.
104. Ourique AF, Pohlmann AR, Guterres SS, Beck RCR. Tretinoin-loaded nanocapsules: Preparation, physicochemical characterization, and photostability study. Int J Pharm. 2008;352:1-4.
105. Agrawal Y, Petkar KC, Sawant KK. Development, evaluation and clinical studies of Acitretin loaded nanostructured lipid carriers for topical treatment of psoriasis. Int J Pharm. 2010;401:93-102.
106. Barry BW. Novel mechanisms and devices to enable successful transdermal drug delivery. Eur J Pharm Sci. 2001;14:101-14.
107. Dubey V, Mishra D, Dutta T, Nahar M, Saraf DK, Jain NK. Dermal and transdermal delivery of an anti-psoriatic agent via ethanolic liposomes. J Cont Rel. 2007;123:148-54.
108. Fang Yi-Ping, Huang Yaw-Bin, Wu Pao-Chu, Tsai Yi-Hung. Topical delivery of 5-aminolevulinic acid-encapsulated ethosomes in a hyperproliferative skin animal model using the CLSM technique to evaluate the penetration behaviour. Eur J Pharm Biopharm. 2009;73:391-8.
109. Boehncke Wolf-Henning, Schön MP. Animal models of psoriasis. Clin Dermatol. 2007;25:596-605.
110. Raychaudhuri SP, Dutt S, Raychaudhuri SK, Sanyal M, Farber EM. Severe combined immunodeficiency mouse-human skin chimeras: a unique animal model for the study of psoriasis and cutaneous inflammation. Br J Dermatol. 2001;144:931-9.
111. Wolf-Henning Boehncke, Michael P. Schön. Animal models of psoriasis. Clin Dermatol. 2007; 25:596-605.
112. Zheng Y, Eilertsen KJ, Ge L, Zhang L, Sundberg JP, Prouty SM. Scd1 is expressed in sebaceous glands and is disrupted in the asebia mouse. Nat Genet. 1999;23:268-70.
113. Levy DE, Darnell JE Jr. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol. 2002;3:651-62.
114. Sano S, Chan KS, Carbajal S, Clifford J, Peavey M, Kiguchi K. Stat3 links activated eratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat Med. 2005;11:43-9.
115. Li AG, Wang D, Feng XH, Wang XJ. Latent TGF-beta1 overexpression in keratinocytes results in a severe psoriasis-like skin disorder. EMBO J. 2004;23:1770-81.
116. Hobbs RM, Silva-Vargas V, Groves R, Watt FM. Expression of activated MEK1 in differentiating epidermal cells is sufficient to generate hyperproliferative and inflammatory skin lesions. J Invest Dermatol. 2004;123:503-15.
117. Kunstfeld R, Hirakawa S, Hong YK, Schacht V, Lange-Asschenfeldt B, Velasco P. Induction of cutaneous delayed-type hypersensitivity reactions in VEGF-A transgenic mice results in chronic skin inflammation associated with persistent lymphatic hyperplasia. Blood. 2004;104:1048-57.
118. Voskas D, Jones N, Van Slyke P, Sturk C, Chang W, Haninec A. A cyclosporine-sensitive psoriasis-like disease produced in Tie2 transgenic mice. Am J Pathol. 2005;166:843-55.
119. Schon MP, Schon M, Warren HB, Donohue JP, Parker CM. Cutaneous inflammatory disorder in integrin alphaE (CD103)-deficient mice. J Immunol. 2000;165:6583-9.
120. Sigmundsdottir H, Johnston A, Gudjonsson JE, Valdimarsson H. Differential effects of interleukin 12 and interleukin 10 on superantigen-induced expression of cutaneous lymphocyte-associated antigen (CLA) and alphaEbeta7 integrin (CD103) by CD8+ T cells. Clin Immunol. 2004;111:119-25.
121. Boyman O, Hefti HP, Conrad C, Nickoloff BJ, Suter M, Nestle FO. Spontaneous develop ment of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-alpha. J Exp Med. 2004;199:731-6.
122. Leman JA, Burden AD. Recognition and treatment of psoriasis in children. Curr Paediat. 2003;13:418-22.
123. Saurat JH, Stingl G, Dubertret L, Papp K, Langley RG, Ortonne JP, Unnebrink K, Kaul M, Camez A. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2008; 158:558-66.
124. Murphy FP, Coven TR, Burack LH, Gilleaudeau P, Cardinale I, Auerbach R, Krueger JG. Clearing of psoriasis by 6-thioguanine correlates with cutaneous T-cell depletion via apoptosis. Arch Dermatol. 1999;135:1495-502.
125. Allison AC, Eugui EM. Mycophenolate mofetil, a rationally designed immunosuppressive drug. Clin Transplant. 2002;7:96-112.
126. Federman DG, Froelich CW. Topical psoriasis therapy. Am Fam Physician. 1999;59:957-62.
127. Julien Hanson, Andreas Gille, Sabrina Zwykiel, Martina Lukasova, Björn E Clausen, Kashan Ahmed, Sorin Tunaru, Angela Wirth, Stefan Offermanns. Nicotinic acid-and monomethyl fumarate-induced flushing involves GPR109A expressed by keratinocytes and COX-2-dependent prostanoid formation in mice. J Clin Invest. 2010;120(8):2910-9.
128. Balato A, La Bella S, Gaudiello F, Balato N. Efalizumab-induced guttate psoriasis. Successful management and re-treatment. J Dermatol Treat. 2008; 19:182-4.
129. Jullien D, Prinz JC, Langley RG, Caro I, Dummer W, Joshi A, Dedrick R, Natta P. T-cell modulation for the treatment of chronic plaque psoriasis with Efalizumab (Raptiva): mechanisms of action. Dermatol. 2004;208:297-306.
130. Igney FH, Asadullah K, Zollner T. Humanised mouse models in drug discovery for skin inflammation. Expert Opin Drug Discov. 2006;1:53-68.
131. Carlin CS, Feldman SR, Krueger JG, Menter A, Krueger GG. A 50% reduction in the psoriasis area and severity index is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol. 2004;50:859-66.
132. Gaylor ML, Duvic M. Generalized pustular psoriasis following withdrawal of efalizumab. J Drugs Dermatol. 2004;3:77-9.
133. Thomas VD, Yang FC, Kvedar JC. Biologics in psoriasis: a quick reference guide. J Am Acad Dermatol. 2005;53:346-51.
134. Reich K, Nestle FO, Papp K, Ortonne J, Evans R, Guzzo C, Shu L, Dooley LT, Griffiths CEM. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005;366:1367-74.
135. Gordon KB, Bonish BK, Patel T, Leonard CL, Nickoloff BJ. The tumor necrosis factor-alpha inhibitor adalimumab rapidly reverses the decrease in epidermal Langerhans cell density in psoriatic plaques. Br J Dermatol. 2005;153:945-53.
136. Berthelot CN, George SJ, Hsu S. Distal lower extremity paresthesia and foot drop developing during adalimumab therapy. J Am Acad Dermatol. 2005;53:S260-S262.
137. Kimball AB, Gordon KB, Langley RG. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. Arch Dermatol. 2008;144:200-7.
138. Owen CM, Harrison PV. Successful treatment of severe psoriasis with basiliximab, an interleukin-2 receptor monoclonal antibody. Clin Exp Dermatol. 2000;25:195-7.
139. Abrams JR, Kelley SL, Hayes E, Kikuchi T, Brown MJ, Kang S. Blockade of T lymphocyte co stimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J Exp Med. 2000;92:681-94.
140. Gottlieb AB, Lebwohl M, Shirin S, Sherr A, Gilleaudeau P, Singer G, Solodkina G, Grossman R, Gisoldi E, Phillips S, Neisler HM, Krueger JG. Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: results of a pilot, multi-center, multiple-dose, placebo-controlled study. J Am Acad Dermatol. 2000;43:595-604.
141. Winterfield L, Menter A. Psoriasis and its treatment with infl iximab-mediated tumor necrosis factor alpha blockade. Dermatol Clin. 2004;22:437-47.
142. Gillian S, Samah NA, Zulfakar MH, Yurdasiper A, Heard CM. Enhanced topical delivery and anti-inflammatory activity of methotrexate from an activated nanogel. Euro J Pharm Biopharm. 2010;76: 275-81.
143. Srisuka P, Thongnopnua P, Raktanonchai U, Kanokpanont S. Physico-chemical characteristics of methotrexate-entrapped oleic acid-containing deformable liposomes for in vitro transepidermal delivery targeting psoriasis treatment. Int J Pharm. 2012;427:426-34.
144. Bernardi DS, Pereira TA, Naira R Maciel, Josiane Bortoloto, Gisely S Viera, Gustavo C Oliveira, Pedro A Rocha-Filho. Formation and stability of oil-in-water nanoemulsions containing rice bran oil: in vitro and in vivo assessments. J Nanobiotech. 2011: doi:10.1186/1477-3155-9-44.
145. Behera J, Keservani RK, Yadav A, Tripathi M, Chadoker A. Methoxsalen loaded chitosan coated microemulsion for effective treatment of psoriasis. Int J Drug Deliv.2010;2:159-67.
146. Trotta M, Peira E, Carlotti ME, Gallarate M. Deformable liposomes for dermal administration of methotrexate. Int J Pharm. 2004;270:119-25.